Agendia BV Appoints Clinical and Scientific Advisory Board
29/10/2007 17:54
PR Newswire
AMSTERDAM, October 29 /PRNewswire/ --
- Six Eminent Cancer Researchers Advise Agendia
Agendia BV, a world leader in the rapidly evolving field of cancer
molecular diagnostics has appointed six members to its Clinical and
Scientific Advisory Board. The newly established Clinical and Scientific
Advisory Board is comprised of internationally-recognized scientists with
research and clinical expertise. The advisors review early research programs
and provide critical evaluations from academic and clinical perspectives.
Agendia welcomes:
Piet Borst (chair), M.D., PhD, CBE, For Mem RS, Staff Member and Emeritus
Director of the Netherlands Cancer Institute and Professor of Clinical
Biochemistry, Amsterdam, The Netherlands
Jose Baselga M.D., Professor of Medicine and Chairman of the medical
oncology service, Vall d'Hebron University Hospital, Barcelona, Spain
Matt van de Rijn, M.D., Ph.D, Professor of Pathology, Stanford
University, School of Medicine, Stanford, CA, USA
David Kerr M.D., Professor of Clinical Pharmacology, University of
Oxford, Radcliffe Infirmary, Oxford, UK
C. Kent Osborne, M.D., Professor of Medicine and, Director, Breast Center
Baylor College of Medicine, Houston, Texas, USA, Director, Dan L. Duncan
Cancer Center at Baylor College of Medicine
Joe W. Gray, Ph.D., Director, Life Sciences Division, Lawrence Berkeley
National Laboratory, Berkeley, CA, USA and Professor UCSF Comprehensive
Cancer Center.
"We are very pleased that this outstanding group of scientist-clinicians
has agreed to join Agendia's clinical and scientific advisory board", says
Prof. dr. Rene Bernards, Chief Scientific Officer at Agendia. "Their insights
into the clinical needs of cancer patients will help us to tailor our product
portfolio to best serve patients and their doctors to optimize the treatment
for each individual patient."
"The addition of these six distinguished scientists and clinicians will
enable us to further strengthen strategies in cancer and other diseases" said
Dr. Bernhard Sixt, Chief Executive Officer at Agendia.
About Agendia
Agendia, located in Amsterdam, the Netherlands, is a world leader in gene
expression analysis-based diagnostics with three products on the market. The
company focuses on the development and commercialization of diagnostic tests
using tumor gene expression profiling. Agendia was the first company to
obtain FDA approval for it's breast cancer test - MammaPrint(R) - that
predicts the risk of breast cancer recurrence. Its second microarray product,
CupPrint(R)(i), is a diagnostic test to identify the origin of a metastasis in
a cancer type called "Cancer of Unknown Primary". Agendia recently also
presented its new colon cancer prognosis profile, ColoPrint(R), which is
currently undergoing further validation. Agendia maintains close ties with
several leading academic centers to develop state of the art diagnostic tests
for cancer. Agendia also offers its expertise to pharma companies focusing on
development of highly effective personalized drugs in the area of oncology.
(i) CupPrint(R) is based on a license to the TUO database of AviaraDx
Contact Information: Agendia: Prof.dr. Rene Bernards, Chief Scientific Officer at +31-626-558-679